ReviewNature reviews. Cardiology2022
Repurposing drugs to treat cardiovascular disease in the era of precision medicine.
Review in Nature reviews. Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.Journal of nanobiotechnology · 2026Pooled it
- Tamoxifen may contribute to preserve cardiac function in Duchenne muscular dystrophy.European journal of pediatrics · 2024Trial
- An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis.Applied health economics and health policy · 2026Article
- Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine.ChemMedChem · 2026Review
- From the Proteome to Therapeutics: A Multi-Database Approach to Drug Discovery in Periodontitis-An Exploratory Pilot Study.Journal of clinical periodontology · 2026Article
- Advancing target discovery through disease-specific integration of multi-modal target identification models and comprehensive benchmarking system.Scientific reports · 2026Article
- AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease.Nature communications · 2026Article
- Drug repurposing: a promising drug discovery strategy for the treatment of emerging epidemic infectious disease.Molecular diversity · 2026Review
- Narciclasine Alleviates Endothelial Inflammation and Atherosclerosis Initiation by Inhibiting Histone Lactylation-Mediated NF-κB Activation.Inflammation · 2026Article
- Comic: explainable drug repurposing via contrastive masking for interpretable connections.BMC bioinformatics · 2026Article
- Scalable differentiation of human cardiac organoids from iPSCs generates cardiac tissues for cardiac cell therapy.Theranostics · 2026Article
- Computational insights on drug effects on intrinsic stochasticity of mouse pacemaker cell activity.Biophysical journal · 2025Article
- Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect.Biomedicines · 2025Review
- Article
- Restoration of NOX4 signalling reverses endothelial colony-forming cell angiogenic dysfunction associated with experimental and clinical diabetes.Stem cell research & therapy · 2025Article
- Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches.Proteomics · 2025Article
- Navigating the Landscape of Translational Medicine of Calcific Aortic Valve Disease: Bridging Bench to Bedside.JACC. Asia · 2025Review
- Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Drug Repurposing and Nanotechnology for Topical Skin Cancer Treatment: Redirecting toward Targeted and Synergistic Antitumor Effects.ACS pharmacology & translational science · 2025Review
- Conductive Microfibers Improve Stem Cell-Derived Cardiac Spheroid Maturation.Journal of biomedical materials research. Part A · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine - computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities - support efforts that together create an efficient pipeline to systematically repurpose drugs to treat cardiovascular disease. Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created a new landscape of opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.